Novo Nordisk's Denecimig (Mim8) Demonstrated Positive Results in Long Term Safety and Efficacy in Phase 3 Hemophilia A FRONTIER Extension Study

Дата публикации: 11-07-2026 03:07:12

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, July 11, 2026 /PRNewswire/ -- Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8)...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
2	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks	0	17.66	06-07-2026
3	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	0	12.36	14-06-2026
4	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	11.39	29-04-2026
5	Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	13.2	08-07-2026
6	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease	0	13.04	14-07-2026
7	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema	0	15.53	27-04-2026
8	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	0	13.9	30-07-2026
9	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	0	9.64	22-06-2026
10	Efzimfotase Alfa Demonstrated Improvements in Bone Health in Treatment-Naïve Pediatric Patients with Hypophosphatasia in MULBERRY Phase III Trial	0	12.32	28-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 15.61. Источник: www.drugs.com.